Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness AnalysisShow others and affiliations
2021 (English)In: Diabetes Therapy, ISSN 1869-6953, E-ISSN 1869-6961, Vol. 12, no 1, p. 373-388
Article in journal (Refereed) Published
Abstract [en]
INTRODUCTION: Real-world evidence has demonstrated improved glycemic control and insulin management following introduction of smart insulin pens in a Swedish type 1 diabetes (T1D) population. To understand the implications for healthcare costs and expected health outcomes, this analysis evaluated the long-term cost-effectiveness of introducing smart insulin pens to standard-of-care T1D treatment (standard care) from a Swedish societal perspective.
METHODS: Clinical outcomes and healthcare costs (in 2018 Swedish krona, SEK) were projected over patients' lifetimes using the IQVIA CORE Diabetes Model to estimate cost-effectiveness. Clinical data and baseline characteristics for the simulated cohort were informed by population data and a prospective, noninterventional study of a smart insulin pen in a Swedish T1D population. This analysis captured direct and indirect costs, mortality, and the impact of diabetes-related complications on quality of life.
RESULTS: Over patients' lifetimes, smart insulin pen use was associated with per-patient improvements in mean discounted life expectancy (+ 0.90 years) and quality-adjusted life expectancy (+ 1.15 quality-adjusted life-years), in addition to mean cost savings (direct, SEK 124,270; indirect, SEK 373,725), versus standard care. A lower frequency and delayed onset of complications drove projected improvements in quality-adjusted life expectancy and lower costs with smart insulin pens versus standard care. Overall, smart insulin pens were a dominant treatment option relative to standard care across all base-case and sensitivity analyses.
CONCLUSIONS: Use of smart insulin pens was projected to improve clinical outcomes at lower costs relative to standard care in a Swedish T1D population and represents a good use of healthcare resources in Sweden.
Place, publisher, year, edition, pages
Springer, 2021. Vol. 12, no 1, p. 373-388
Keywords [en]
Diabetes complications, Diabetes self-management, Diabetes technology, Digital health, Health technology assessment, Healthcare economics, Hypoglycemia, Insulin therapy, Type 1 diabetes, eHealth
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-88081DOI: 10.1007/s13300-020-00980-1ISI: 000597771500001PubMedID: 33306169Scopus ID: 2-s2.0-85097506144OAI: oai:DiVA.org:oru-88081DiVA, id: diva2:1511097
Funder
Novo Nordisk2020-12-172020-12-172023-12-08Bibliographically approved